Everything tagged "animal health" across the TickerSpark archives.
Phibro Animal Health is executing well after the Zoetis portfolio acquisition, with double-digit sales and EBITDA growth. But elevated leverage and regulatory exposure keep the stock in Hold territory.
Zoetis’ 5.97% selloff looks like a concentrated U.S. pet-demand reset, not a broken animal-health franchise. At 12.39x trailing earnings and a 37.0% operating margin, ZTS offers long-term bulls a better entry than its old premium valuation did.
ELAN’s 8.6% post-earnings drop on 2.8x relative volume looks less like a fresh opportunity than a market warning. The turnaround is real, but the stock is not yet earning a rerating.
Elanco is showing real momentum from Zenrelia and Credelio Quattro, with 2026 guidance rising and organic growth improving across pet and farm animal lines. The stock still carries meaningful balance-sheet risk, so the upside case depends on execution and debt reduction.
Zoetis remains a Buy for investors willing to wait for a premium pet-care rebound. Strong margins, cash flow, and a deep pipeline are offset by softer U.S. companion-animal trends and elevated leverage.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime